Table 3.

 Post-ablation drug use and relation with AF development

	Number of patients	Univariate analysis		Multivariate analysis
		RR (95% CI)	p Value	RR (95% CI)	p Value
Class I drugs	56 (29%)	1.96 (1.33 to 2.87)	<0.01	1.66 (1.06 to 2.60)	0.03
Class III drugs	74 (38%)	0.86 (0.58 to 1.26)	0.43	0.76 (0.50 to 1.19)	0.23
AV node slowing drugs	85 (43%)	1.22 (0.85 to 1.78)	0.29	0.97 (0.66 to 1.44)	0.89
ACE inhibitors/ARB	46 (23%)	0.62 (0.37 to 0.99)	0.04	0.55 (0.31 to 0.97)	0.04
Diuretics	27 (14%)	0.34 (0.16 to 0.70)	<0.01	0.28 (0.13 to 0.63)	<0.01
Other antihypertensive drugs	85 (43%)	1.01 (0.73 to 1.64)	0.67	1.00 (0.70 to 1.58)	0.83

Intention to treat analysis. A patient was classified into a given drug group when the medication was given on day 0 and continued until at least day 30.

Atrioventricular (AV) node slowing drugs: β blockers, verapamil, digitalis. Other antihypertensive drugs: β blocker, dihydropyridine-type calcium antagonists, moxonidine, clonidine.

ACE, angiotensin converting enzyme; ARB: angiotensin II receptor blockers.